Friday, October 19, 2018 3:21:58 PM
As for the question about the Tests and News it takes time to compile and recheck the data prior to submitting the results in a way required by the FDA,
Lex posted long ago what their schedule was and up to know have kept to that forecast, we all know that by end of year early next year the FDA will either grant or deny the Heart Sentry. Be thankful it isn't and invasive procedure for a Drug, because that can take up to 10 years to be approved !!!
Faith and Patience is the key..
This is speculation on my part, However there seems to be a lot of shares traded recently that take the M&M theory out of the equation. It could very well be that the Executive Members of Lexington are selling their shares in order to progress with the trials in order to meet future FDA approval. Which could result in more shares being issued and the Board being allotted a bigger quantity in order to be reimbursed and a receive handsome profit for all there troubles.
I personally will just keep buying and let Lex and the HS take its course, I will either win or loose but that's the way it goes, It will be nice to see a good increase in price, but if it fails that's ok too, I haven't invested anything I can't afford to loose and neither should anyone else..
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM